Last reviewed · How we verify

NCT04122599

Melatonin for Prevention of Post Stroke Delirium

Status unknown Phase 2, PHASE3 Last updated 10 October 2019
What this trial tests

Phase 2, PHASE3 trial testing Melatonin in Post Stroke Delirium in 2,000 participants. Status unknown.

Timeline
1 July 2017
Primary endpoint
1 November 2019
31 December 2019

Quick facts

Lead sponsorUniversity Hospital Tuebingen
PhasePhase 2, PHASE3
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposeprevention
Enrollment2,000
Start date1 July 2017
Primary completion1 November 2019
Estimated completion31 December 2019
Sites1 location across Germany

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital Tuebingen

Who can join

55 and older, any sex, with Post Stroke Delirium. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Post stroke delirium is prevalent in 10-30% of all stroke patients. We aimed to investigate wether Melatonin 2mg may prevent post stroke delirium.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Melatonin

Trials testing the same drug.

Other University Hospital Tuebingen trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04122599.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing